Flu season ends with a whisper, not a bang.

Published Date: 14 Mar 2023

The 2022-2023 flu season is on the edge of life which has been predicted for half of January and most of February.

Read Full News

Latest News

Buridan’s Ass and the Limits of Medical Reasoning

Not every clinical dilemma has a rational answer, and pretending otherwise carries its own risks.

AI Tool Shows Promise for Lung Cancer Response Assessment

An AI algorithm accurately evaluates pathologic response after neoadjuvant chemoimmunotherapy in patients with NSCLC, showing moderate concordance with expert pathologist consensus across cohorts.

9/11-Related Cancers Still Emerging 25 Years Later

Cancer diagnoses among people exposed to the World Trade Center disaster continue to be reported 25 years after 9/11, highlighting the long latency of some WTC-related malignancies.

FDA OKs First Drug to Target Muscle Loss in SMA

Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy.

Admin Hurdles, Not Insurance, Block Bariatric Surgery Access

Secret shopper calls to bariatric programs in two US states find that administrative and scheduling barriers — not insurance — may limit access to initial appointments.

Acute Otitis Media: The Cost of a Common Childhood Infection

Dr. Pichichero discusses the financial and health costs of acute otitis media.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Latest News

Not every clinical dilemma has a rational answer, and pretending otherwise carries its own risks.

An AI algorithm accurately evaluates pathologic response after neoadjuvant chemoimmunotherapy in patients with NSCLC, showing moderate concordance with expert pathologist consensus across cohorts.

Cancer diagnoses among people exposed to the World Trade Center disaster continue to be reported 25 years after 9/11, highlighting the long latency of some WTC-related malignancies.

Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy.

Secret shopper calls to bariatric programs in two US states find that administrative and scheduling barriers — not insurance — may limit access to initial appointments.

Dr. Pichichero discusses the financial and health costs of acute otitis media.

News All Time

Disparities in Urban and Rural Mortality from Non-Melanoma Skin Cancers

This study assessed differences in age-adjusted mortality rates in nonmelanoma skin cancer in U.S. urban and rural populations.

Improving Resident Attitudes Toward Patients with SCA

This study evaluated whether a CAB-designed educational intervention could improve resident physician attitudes toward patients with SCA.

Does This New Clue Explain the Smoking-Parkinson’s Mystery?

Carbon monoxide may help explain the long-observed but perplexing association between smoking and a lower risk for Parkinson’s disease.

Cancer Screening Lower for Adults With Disabilities

A new study finds millions of adults with disabilities are missing critical cancer screenings, but those with disabilities have higher rates of at-home stool testing for colorectal cancer.

Early Remdesivir May Protect Kidney Grafts After COVID

Early antiviral intervention is associated with lower risks for graft loss and cardiovascular events in kidney transplant recipients with COVID.

The Future of Oncology Clinical Pathways in VHA

VA oncology Clinical Pathways logged 26,613 entries for 11,835 patients in FY25, standardizing care and paving the way to Oracle Health EHR.

Normal, but Not Optimal: Rethinking Perimenopause

In this roundtable, Drs Rachel Rubin, Makeba Williams, and Anna Cabeca discuss the changing landscape of perimenopause care — and why every clinician should join the conversation.

Inflammation on Imaging May Help Predict Hand OA Progression

Synovitis detected using ultrasonography and MRI is associated with increased odds of structural worsening in thumb base and finger joints in patients with hand osteoarthritis.

Allo-HSCT Shows Long-Term Benefit in Hepatosplenic Lymphoma

Researchers examine the roles of allogeneic and autologous HSCT in patients with hepatosplenic T-cell lymphoma and identify factors linked to survival after transplantation.

Insomnia Diagnoses, Rx Surge in Catalan Primary Care

Insomnia diagnoses and related pharmacologic prescriptions show a rise among adults in Central Catalonia; those with insomnia and polypharmacy are more likely to receive pharmacologic treatment.

Cenobamate May Offer Benefits in Rare Childhood Epilepsy

Cenobamate is linked to sustained seizure control and higher treatment retention rates over 12 months in children with developmental and epileptic encephalopathies.

Can Antiviral PEP Protect Workers During Ebola Outbreaks?

Rapid delivery of antiviral post-exposure prophylaxis at high coverage could substantially reduce deaths among healthcare workers during orthoebolavirus outbreaks, a modeling study suggests.

SMC Extends SMA Drug Access to Newborns

The Scottish Medicines Consortium extends nusinersen access to pre-symptomatic 5q SMA infants after trial data showed most learned to walk.

Vaccines Worked for Decades: Why Are Diseases Returning?

Measles, diphtheria, and polio are reappearing in places where vaccination once kept them at bay, raising concerns about declining coverage and immunity gaps.

A Novel Virtual Culinary Program for Veterans With Cancer

A single virtual cooking class helped veterans in oncology care manage appetite loss and weight change, with 9.3/10 satisfaction in this VA pilot.

Low-Dose Sq Decitabine ± Venetoclax in Myeloid Malignancies

Across 4 VA sites, 22 veterans with AML, MDS, or CMML tolerated low-dose sq decitabine±venetoclax, showing feasibility in a hard-to-treat population.

Recommended News For You

In breast cancer patients with nodes positive, preoperative hydroxyprogesterone may enhance disease-free survival.

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

Preoperative Embolization Linked to Relapse-Free Survival in Meningioma

Palliative Care Remains Uncommon in Young Adults With Cancer

Higher Binge Drinking Rates Linked to New Cannabis Laws.

The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.

Recommended Articles For You

Guidance for Managing Complex Anticoagulation 

Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients 

The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond 

Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New research demonstrates a method for screening people at high risk for pancreatic cancer.

2.

A paper strip test might enable the early detection of cancer.

3.

Pickleball program boosts health and wellness for cancer survivors, study finds

4.

Advancing Health in Africa

5.

GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.

1.

Environmental Carcinogen Exposure Risk Modeling: Current Evidence and Clinical Implications

2.

Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk

3.

Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options

4.

The Science Behind Imatinib: How It Targets Cancer Cells 

5.

What You Need to Know About the Early Warning Signs of Colon Cancer 

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

2.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

3.

Emerging Concepts in Hematology

4.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

5.

Signs and Symptoms of Leukemia

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot